Law360, San Diego (August 08, 2011, 4:17 PM ET) -- A Texas federal judge ruled Friday that Par Pharmaceutical Cos. Inc. and two other drugmakers had infringed Pozen Inc.'s patents covering the migraine treatment Treximet and barred them from selling generic versions of the drug in the U.S. until certain patents expire.
U.S. District Court Judge Leonard Davis determined that Pozen’s three patents — U.S. Patent Numbers 6,060,499; 6,586,458; and 7,332,183 — were valid and infringed by Par and Dr. Reddy’s Laboratories Ltd. The judge also held that Alphapharm Pty Ltd. violated the two patents asserted...
Pozen Wins Injunction On Generic Treximet
To view the full article, take a free trial now.
